Intra-Cellular Therapies, Inc.
ITCI
Helyezés a részvények között
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Részvényárfolyam
$131.87
Utolsó szinkronizálás: 2025-04-02
Piaci kapitalizáció
$12.68B
Változás (1 nap)
0.00%
Változás (1 év)
0.00%
Ország
US
Kereskedés Intra-Cellular Therapies, Inc. (ITCI)
Kategória
Healthcare
EPS Intra-Cellular Therapies, Inc. (ITCI) részvényre
EPS December 2024 dátummal, TTM: $-0.01
Intra-Cellular Therapies, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $-0.01. 2023 végén a vállalat EPS mutatója $-1.46 volt, csökkenés a 2022 év EPS értékéhez, amely $-2.72 volt.
Intra-Cellular Therapies, Inc. EPS története 2013 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $-0.01 | -98.61% |
| 2024 | $-0.72 | -50.68% |
| 2023 | $-1.46 | -46.32% |
| 2022 | $-2.72 | -22.29% |
| 2021 | $-3.50 | 8.36% |
| 2020 | $-3.23 | 20.52% |
| 2019 | $-2.68 | -5.63% |
| 2018 | $-2.84 | 33.96% |
| 2017 | $-2.12 | -21.19% |
| 2016 | $-2.69 | -7.56% |
| 2015 | $-2.91 | 171.96% |
| 2014 | $-1.07 | -31.41% |
| 2013 | $-1.56 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -5,663.00% |
IN
|
